Clinical Trial Search

Primary: Number and Percentage of Participants With Evidence of Chronic Ongoing Synovial-Based Inflammatory Disease at Baseline. — 63 Participants — p=0.34

Primary: Change in Pain Intensity — 3.5; 3.8 units on a scale

Primary: Change From Baseline to Day 2 in Patient's Assessment of Pain Intensity — 3.03; 2.73; 2.84; 2.83 Scores on a scale

Primary: Mean Change From Baseline to Month 24 in the Modified Sharp/Van Der Heijde Erosion Score of the Single Affected Joint — 0.16; 0.11; 0.01; 0.01 score on a scale — p=0.472

Primary: Disease Activity Score Based on 28-joint Disease Activity Score (DAS28) — 4.40; 4.03; 4.57; 4.48 units on a scale

Primary: Uric Acid Level — 8.23; 8.03 mg/dL

Primary: Measurement of Tophi by MRI - Difference in Volument Between Visits — -0.05 centimeters³ (cm³) — p=0.785

Primary: sUA < 6.0 mg/dl at 1 Year — 117; 204 Participants

Primary: Number of Gout Flares Per Subject — 3.02; 2.45 flares — p=0.1356

Primary: Change in Patient-assessed Pain Intensity in the Index Joint From Baseline to 24-72 Hours for the First Gout Flare Treated in the Study as Measured by VAS — -26.1…

Primary: Factors Associated With Eaton Classification of Trapeziometacarpal Arthrosis: Age — 61; 66; 75 Years

Primary: Preference IVR vs RheumPRO — 3; 28 Participants

Primary: Average Percent Difference in Area Between Visits — 29 mm²

Primary: Percentage of Participants Achieving Target Urate Levels (24 Weeks) — 29; 3 Participants

Primary: CT Bone Erosion Score — 6.6; 7.0 Score on a scale

Primary: Numeric Pain Rating Scale — 1.7; 2.4; 3.2 units on a scale — p=0.6

Primary: Investigate Whether a 6 Month Course of Combined Antibiotics Was Effective Treatment. — 10; 7; 3 participants — p=0.01

Primary: Percentage of Participants Experiencing ≥ 1 Gout Flare During Phase 3 — 135; 165 Participants — p=<0.001

Primary: Reduction in Plasma Uric Acid to Less Than 6 mg/dL. — 17 Participants

Primary: Number of Participants Who Reported Adverse Events — 78; 65; 64 Participants

Primary: Percent Changes of Serum Uric Acid Levels From Baseline Levels — -30.93; -49.91; -54.32; -2.05 Percent change — p=<0.0001

Primary: Change in Tissue Sodium — 17.1; 16.7 mmol/L — p=0.55

Primary: Serum Urate Maximum Percentage (%) Change (Emax, CB) — -43.5; -55.6; -70.4; -79.1 Percentage (%) — p=<0.0001

Primary: Percentage of Participants With sUA (Serum Uric Acid) < 5.0 mg/dL at Day 84 — 47.1; 44.7; 62.2; 2.9 Percentage of participants

Primary: Cohort 1 - Maximum Percentage (%) Change in Serum Urate of Multiple-dose RDEA3170 Administered in Combination With Allopurinol (Emax, CB (%)) — -40.2; -55.0; -56.8…

Primary: Proportion of Subjects Achieving Serum Uric Acid Concentration <6.0 mg/dL — 33; 43 Participants

Primary: Plasma Uric Acid (PUA) Responder — 36; 29; 0 Participants — p=<0.001

Primary: Alteration of Microbiota, Alteration of T Cell Function/Activation — 4; 10; 2; 0 participants

Primary: Number of Subjects Achieving an American College of Rheumatology 20 (ACR20) Response (20% Improvement) — 18; 8 Participants — p=0.0352

Primary: Safety and Tolerability of Multiple Intravenous Infusions of SEL-037 or SEL-212 as Assessed by the Percentage of Participants Experiencing Serious Adverse Events and…